EGFR and cancer: Our data indicated that digoxin suppresses FAK-Src, paxillin, PI3K/AKT, MEK/ERK, STAT3 and p130Cas-JNK signaling pathways in various EGFR-containing lung cancer cells, suggesting that digoxin inhibits cancer cell invasion by decreasing Src activation and the activation of related signaling pathways.